A recent study demonstrated, that SRSF2 mutations can impair JAK2-V617F signaling by missplicing of JAK2 leading to reduced TGF-β levels and attenuation of myelofibrosis [256]. This evidence concerns the gene JAK2 and myelofibrosis.